Background
HIV Elite controllers (EC) suppress HIV viremia without ART, yet previous studies demonstrated that EC maintain an activated T cell phenotype. Chronic immune activation has detrimental consequences and thus ART has been advocated for all EC. However, EC is not a clinically homogenous group. Since CD4% is among the best predictors of AIDS related events, in the current study, we assessed whether this marker can be used to stratify EC needing ART.
Methods
Sixteen EC were divided into 2 groups based on CD4% (EChi>40% and EClo ≤40%), and T cell subsets were analyzed for markers of memory/differentiation (CD45RA, CCR7, CD28), activation (CD38/HLA-DR), immunosenescence (CD57), co-stimulation (CD73, CD28) and exhaustion (PD-1, CD160, Tim-3). Monocyte subsets (CD14, CD16) were also analyzed and sCD14 levels were quantified using ELISA.
Results
In the EChi group, expression of activation, exhaustion, and immunosensescence markers on T cells were significantly reduced compared to the EClo group and similar to the seronegative controls. The EChi group expressed higher levels of co-stimulatory molecules CD28 and CD73 and had lower levels of monocyte activation (HLA-DR expression) with a reduced frequency of inflammatory monocyte (CD14++CD16+) subset. Furthermore, the EChi group maintained a stable CD4% during a median follow up of six years.
Conclusions
Elite controllers with preserved CD4 T cells (EChi) have normal T cell and monocyte phenotypes and therefore may have limited benefit from antiretroviral therapy (ART). CD4% can be an important marker for evaluating future studies aimed at determining the need for ART in this group of individuals.